|
STATEMENT OF NEED
SUCCEED will use case studies and video vignettes to explore practical issues in the accurate diagnosis and evidence-based management of complicated depressive disorders, including Major Depressive Disorder (MDD) and bipolar depression. Depressive symptoms, as a result of unipolar or bipolar illness, continue to profoundly impact U.S. adults.1,2 Although depressive symptoms are similar in various conditions (persistent sad feelings, feelings of hopelessness, irritability, sleep/appetite changes), their clinical presentation, comorbidities, treatment, and outcomes may differ depending on the cause. The importance of achieving remission cannot be overstated when treating complicated depression. Those who achieve symptomatic remission experience greater improvement in functioning (and commensurate improvement in disability) than those who obtain some response without full remission.3 Treating only to "response" leaves the patient with residual symptoms and can lead to a greater risk for relapse and recurrence, more chronic depressive episodes, a shorter duration between episodes, and continued impairment in work and relationships.4 Bipolar depression may be misdiagnosed as unipolar depression if the patient is introduced to the health care system during a depressive cycle. Accurate history taking, including use of tools to assess for previous manic or hypomanic episodes, can improve diagnostic accuracy and treatment response.5 Accurate diagnosis involves obtaining patient history of depressive symptoms and features, family psychiatric history, course of illness and treatment response. Tools such as the Mood Disorder Questionnaire (MDQ) and the World Health Organization Composite International Diagnostic Interview (CIDI) 3.0 may assist the clinician in screening for bipolarity and will be employed in this training.6 Differentiating bipolar from unipolar depression is critical due to the considerable length of time patients may suffer with depressive symptoms and the dramatic suicide risk that may be as much as 37-fold higher during this phase of illness.7 Join us to review engaging videos and to discuss detailed, case examples of how to best implement evidence-based strategies into clinical plans in order to optimize overall care of these patients. 1Kessler RC, et al. Arch Gen Psychiatry. 2005; 2U.S. Census Bureau 2005; 3Trivedi MH, et al. Int Clin Psychopharmacol. 2009; 4Judd LL, et al. Am J Psychiatry. 2000; 5Muzina DJ, et al. Ann Clin Psychiatry. 2007; 6Manning JS. Prim Care Companion J Clin Psychiatry. 2010; 7Valtonen HM, et al. Bipolar Disord. 2008.
AGENDA
FACULTY*
Roger S. McIntyre, MD, FRCPC (Activity Chair)
Head, Mood Disorders Psychopharmacology Unit University Health Network Associate Professor of Psychiatry & Pharmacology University of Toronto Toronto, ON
Claudia F. Baldassano, MD
Assistant Professor of Psychiatry University of Pennsylvania Penn Behavioral Health Philadelphia, PA
J. Sloan Manning, MD
Adjunct Associate Professor University of North Carolina Chapel Hill, NC Co-Director, Mood Disorder Clinic Moses Cone Family Practice Residency Greensboro, NC Expert faculty have reviewed educational content for accuracy, currency, and fair balance.
TARGET AUDIENCE
Physicians, NPs, PAs, clinical pharmacists, and other clinicians who practice in psychiatry and primary care who are involved in diagnosing and treating patients with complicated depression.
LEARNING OBJECTIVES
At the conclusion of this application-based activity, participants should be able to:
This activity will include audience response keypad participation and case-based video vignettes.
ACCREDITATION STATEMENT
Medicine
Pharmacy
AAFP This activity has been reviewed and is accepted for up to 1.5 Prescribed credits by the American Academy of Family Physicians. Physicians should only claim credit commensurate with the extent of their participation in the activity. Statements of credit will be issued to those who complete a CE request form.
CONTACT US
|
REGISTRATION
To view more details about your city and venue location, click on the city below:
Creative Educational Concepts, Inc. (CEC) reserves the right to cancel or change dates, speakers, content, and/or other details without notice. Furthermore, CEC reserves the right to refuse service to any person at CEC’s sole discretion, subject to applicable law. CEC and AstraZeneca are not responsible for speakers’ or participants’ statements, materials, acts, or omissions not previously approved by CEC. |
Creative Educational Concepts, Inc. (CEC) is accredited by the
Accreditation Council for Continuing Medical Education (ACCME)
to provide continuing medical education for physicians. 
Creative Educational Concepts, Inc. (CEC) is accredited by
the Accreditation Council for Pharmacy Education as a
provider of continuing pharmacy education. This activity has
been assigned ACPE #0245-0000-10-140-L01-P and will award
1.5 contact hours (0.15 CEUs) of continuing pharmacy education
credit. CEC complies with the Criteria for Quality for continuing
education programming.Head, Mood Disorders Psychopharmacology Unit
University Health Network
Associate Professor of Psychiatry & Pharmacology
University of Toronto
Toronto, ON
Dr. McIntyre is currently an Associate Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. He is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders and medical comorbidity. This research involves elucidating metabolic adverse events associated with the use of psychotropic medications, the impact of medical comorbidity on the course of mood disorders, and the effect of glucose homeostasis on neurocognition.
Dr. McIntyre is a contributor to the CPA guidelines for the treatment of depressive disorders and the Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of bipolar disorder. He has published extensively in leading peer-reviewed journals and textbooks. Dr. McIntyre is also a reviewer for many journals including the American Journal of Psychiatry, Biological Psychiatry, Journal of Clinical Psychiatry and The New England Journal of Medicine, and serves as a grant reviewer for the National Institute of Mental Health.
He completed his Medical Degree at Dalhousie University and did his psychiatry residency training and fellowship in psychiatric pharmacology at the University of Toronto.
Dr. McIntyre has disclosed that he is a member of the speakers' bureaus for AstraZeneca, Biovail, Eli Lilly, Ortho-McNeil-Janssen, Lundbeck, and Wyeth. He receives grant/research support from Eli Lilly, Janssen, and Shire.
Assistant Professor of Psychiatry
University of Pennsylvania
Penn Behavioral Health
Philadelphia, PA
Dr. Baldassano is Assistant Professor of Psychiatry, Staff Psychiatrist, and the Director of the Bipolar Outpatient Clinic at the Hospital of the University of Pennsylvania in Philadelphia. She received her undergraduate degree at Duke University in Durham, North Carolina. She received her MD at Pennsylvania State University College of Medicine, in Hershey, Pennsylvania. Her major research interests are bipolar disorder, treatment refractory bipolar depression, and womens issues in bipolar disorder.
She has co-authored articles for scientific journals such as Expert Review of Neurotherapeutics, American Journal of Psychiatry, Journal of Clinical Psychopharmacology, and Depression.
Dr. Baldassano has disclosed that she is a member of the speakers' bureaus for AstraZeneca and Pfizer.
Adjunct Associate Professor
Department of Family Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC
Co-Director, Mood Disorders Clinic
Moses Cone Family Practice Residency
Greensboro, NC
Dr. Manning is Adjunct Associate Professor in the Department of Family Medicine at the University of North Carolina at Chapel Hill. He serves as Co-Director of the Mood Disorders Clinic at the Moses Cone Family Practice Residency in Greensboro, NC. He earned his Medical Degree from the University of Mississippi Medical Center and completed his residency in family practice at Baptist Memorial Hospital in Gadsden, AL. He is Board Certified by the American Board of Family Practice, and is a member of both the American Academy of Family Physicians and the North Carolina Academy of Family Physicians.
Dr. Manning is the founding editor of The Primary Care Companion to The Journal of Clinical Psychiatry, and has authored or co-authored more than 50 letters, articles, and editorials in a variety of journals, including Archives of Family Medicine, Bipolar Disorders, Comprehensive Psychiatry, Journal of Affective Disorders, Journal of Clinical Psychiatry, North American Clinics of Psychiatry, and The Journal of Family Practice. He is also a reviewer for the Journal of Affective Disorders.
His research interests include integrated somatic/mental health care systems in primary care, physician education in primary care psychiatry, and disorders of the bipolar spectrum, including their temperamental underpinnings and pharmacologic management. He was a member of the national coordinating council for the STABLE project, researching performance measures and quality improvement initiatives for bipolar treatment.
Dr. Manning has disclosed that he is a consultant for AstraZeneca, Eli Lilly, PamLab LLC, and Takeda. He is a member of the speakers' bureaus for AstraZeneca and Eli Lilly.
| Presented by Creative Educational Concepts, Inc. | Supported by an independent educational grant from | |
 |
 |